KWF Young Investigator Grant

About the KWF Young Investigator Grant

The KWF Young Investigator Grant (YIG) is the Dutch Cancer Society's flagship funding scheme for early-career cancer researchers based in the Netherlands. Administered by KWF Kankerbestrijding — the country's largest cancer-research charity and a major driver of Dutch oncology funding — it provides up to €600,000 over 4 years to allow recently-independent researchers to establish their own line of oncology research at a Dutch university hospital, comprehensive cancer centre, university, or recognised research institute. The scheme is positioned as the step between a postdoctoral fellowship and a full KWF Research Project grant: applicants are expected to have demonstrated independence from their previous supervisor (typically through first or last author publications without them) but to not yet hold a tenured research-group leadership position. Eligibility is restricted to researchers based at a recognised Dutch research institution with a primary appointment in cancer research broadly defined — basic, translational, clinical, psychosocial, or implementation research are all in scope. Like all KWF schemes, the YIG places explicit emphasis on patient relevance: every proposal must articulate a credible pathway from the laboratory or clinic to patient benefit, and patient or public involvement is encouraged and increasingly expected for clinically-oriented projects. The application runs in two stages: a letter of intent (pre-proposal) reviewed by KWF's scientific advisory bodies, followed by a full proposal stage with international peer review and a final committee decision. Total time from LOI submission to funding decision is approximately 8 to 10 months. The YIG is widely seen as a critical credential for early-career cancer researchers in the Netherlands aiming to establish an independent research line and to position themselves for later KWF Research Project grants or international funding such as the ERC Starting Grant.

Who is eligible?

• •Primary research appointment in cancer research at a recognised Dutch research institution (university, university medical centre, comprehensive cancer centre, or recognised research institute)
• •Demonstrated scientific independence from PhD/postdoc supervisor (typically through first or last author papers without them)
• •Not yet holding a tenured research-group leadership or full professorial position
• •PhD awarded by the call deadline
• •Project plan with clear oncology relevance (basic, translational, clinical, psychosocial, or implementation research)
• •Host institution commitment letter providing infrastructure and embedding the awardee in an active cancer-research environment
• •International collaborators may be included as co-applicants, but the lead applicant must be Dutch-based

How to apply

1. 1. Confirm institutional eligibility and intent

   Speak to your host institution's grants office and your departmental head before drafting. The host signs a commitment letter at the LOI stage and again at full-proposal stage, so internal alignment matters. KWF expects the host to provide research space, core infrastructure, and embedding within an active oncology programme.

2. 2. Draft and submit the letter of intent (pre-proposal)

   The LOI is the gateway. KWF uses it to filter scope, eligibility, and patient-benefit pathway before any full proposal is invited. Keep it focused: one sharp research question, clearly framed within KWF's patient-relevance lens, and an explicit independence narrative that distinguishes your line from your former supervisor's work.

3. 3. Receive LOI feedback and decide on full proposal

   KWF returns LOI decisions with brief feedback. Roughly half of LOIs are invited to full proposal. Use the feedback to sharpen scope and address any structural concerns before committing the months of work that the full proposal requires.

4. 4. Develop the full proposal with patient relevance front-loaded

   The full proposal goes deep on background, objectives, methods, work plan, timeline, budget justification, and ethical considerations. The patient-benefit pathway is a scoring lens, not an afterthought — front-load it in the introduction, restate it in the work plan, and close on it in the impact section. Plain-language summaries (Dutch and English) must be readable by lay panel members.

5. 5. Submit through the KWF portal and wait for external peer review

   Submission is via KWF's online application portal. International peer reviewers score the proposal against KWF's evaluation criteria. The applicant typically receives reviewer comments and is invited to respond before the final committee meeting.

6. 6. Respond to reviewer comments and receive the final decision

   The rebuttal is the last lever before the committee decides. Address every reviewer concern in turn, concede where the criticism is fair, and defend with evidence where it is not. Final funding decisions are communicated 8–10 months after LOI submission.

What sets winning proposals apart

• ✓Front-load patient relevance. KWF is a patient-funded charity and every reviewer reads with that lens. Make the patient-benefit pathway explicit in the introduction, not buried in the impact section.
• ✓Make the independence story unmistakable. Reviewers want to see a research line that is yours, not a continuation of your PhD or postdoc supervisor's programme. Highlight first/last-author papers without them and any independent grants or fellowships already held.
• ✓Match the scope to a single early-career group over 4 years. Overambitious work plans are a recurring rejection signal; the panel prefers focused, deliverable science over a sprawling agenda that even a senior PI would struggle to complete.
• ✓Use plain-language summaries that lay reviewers can score. KWF's scientific committees include patient representatives. A summary that reads as inaccessible jargon costs points before the panel ever opens the science section.
• ✓Involve patient advisors early where the project is clinically oriented. A documented engagement process is increasingly expected for translational and clinical proposals and lifts the patient-relevance score visibly.
• ✓Demonstrate awareness of the Dutch cancer-research landscape. Cite Dutch consortia and infrastructure (Oncode, IKNL, the Netherlands Cancer Registry, university medical centre networks) where relevant. KWF rewards proposals that plug into national capability rather than reinventing it.

Related programmes